|
|
| Line 1: |
Line 1: |
| {{DISPLAYTITLE:Copanlisib dihydrochloride}}
| | #REDIRECT[[Copanlisib]] |
| {{Infobox drug
| |
| | name = Copanlisib dihydrochloride
| |
| | image = Copanlisib_structure.png
| |
| | width = 250
| |
| | alt =
| |
| | caption = Chemical structure of Copanlisib
| |
| | tradename = Aliqopa
| |
| | drugs.com =
| |
| | MedlinePlus =
| |
| | licence_EU =
| |
| | licence_US =
| |
| | pregnancy_AU =
| |
| | pregnancy_US =
| |
| | legal_AU =
| |
| | legal_CA =
| |
| | legal_UK =
| |
| | legal_US = Rx-only
| |
| | routes_of_administration = Intravenous
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism = Hepatic
| |
| | elimination_half-life = 39.1 hours
| |
| | excretion = Feces (64%), urine (22%)
| |
| | CAS_number = 1038935-63-3
| |
| | ATC_prefix = L01
| |
| | ATC_suffix = EM03
| |
| | PubChem = 25142104
| |
| | DrugBank = DB12556
| |
| | ChemSpiderID = 32700806
| |
| | UNII = 1T0N3G9CRC
| |
| | KEGG = D10850
| |
| | ChEMBL = 2103876
| |
| | synonyms = BAY 80-6946
| |
| | IUPAC_name = 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]-5-(triazol-1-yl)benzamide
| |
| }}
| |
| | |
| '''Copanlisib dihydrochloride''' is a [[pharmaceutical drug]] used in the treatment of certain types of [[cancer]], specifically [[relapsed follicular lymphoma]]. It is a [[phosphoinositide 3-kinase]] (PI3K) inhibitor that targets the PI3K pathway, which is often dysregulated in cancer cells.
| |
| | |
| ==Mechanism of Action==
| |
| Copanlisib is a selective inhibitor of the PI3K enzyme, particularly the PI3K-α and PI3K-δ isoforms. The PI3K pathway is involved in cellular functions such as growth, proliferation, and survival. By inhibiting this pathway, copanlisib can induce [[apoptosis]] and inhibit the proliferation of cancer cells.
| |
| | |
| ==Pharmacokinetics==
| |
| Copanlisib is administered intravenously, allowing for direct entry into the bloodstream. It has a half-life of approximately 39.1 hours, which supports its dosing schedule. The drug is primarily metabolized in the [[liver]] and is excreted through feces (64%) and urine (22%).
| |
| | |
| ==Clinical Use==
| |
| Copanlisib is approved for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. It is administered as an intravenous infusion on a weekly basis, with a schedule of three weeks on treatment followed by one week off.
| |
| | |
| ==Adverse Effects==
| |
| Common adverse effects of copanlisib include hyperglycemia, hypertension, diarrhea, decreased general strength and energy, and leukopenia. Serious adverse effects can include severe infections, pneumonitis, and severe cutaneous reactions.
| |
| | |
| ==Contraindications==
| |
| Copanlisib is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with a history of severe infections or those with uncontrolled diabetes or hypertension.
| |
| | |
| ==Drug Interactions==
| |
| Copanlisib may interact with other drugs that affect the [[cytochrome P450]] enzyme system, particularly CYP3A4 inhibitors and inducers. Patients should be monitored for potential interactions that could affect the efficacy or toxicity of copanlisib.
| |
| | |
| ==Research and Development==
| |
| Ongoing research is exploring the use of copanlisib in other types of cancer, including [[chronic lymphocytic leukemia]] and [[solid tumors]]. Clinical trials are investigating its efficacy in combination with other anticancer agents.
| |
| | |
| ==Regulatory Status==
| |
| Copanlisib was granted accelerated approval by the [[U.S. Food and Drug Administration]] (FDA) in 2017 for the treatment of relapsed follicular lymphoma. It is marketed under the trade name Aliqopa. | |
| | |
| ==See Also==
| |
| * [[Phosphoinositide 3-kinase inhibitors]]
| |
| * [[Follicular lymphoma]]
| |
| * [[Cancer treatment]]
| |
| | |
| ==External Links==
| |
| * [FDA Drug Information on Copanlisib]
| |
| * [Clinical Trials on Copanlisib]
| |
| | |
| {{Antineoplastic and immunomodulating drugs}}
| |
| [[Category:Antineoplastic drugs]]
| |
| [[Category:Phosphoinositide 3-kinase inhibitors]]
| |
| [[Category:Quinazolines]]
| |
| [[Category:Drugs with no legal status]]
| |
